Literature DB >> 19275922

Why can sensitization by an HLA-DR2 mismatch lead to antibodies that react also with HLA-DR1?

Marilyn Marrari1, Rene J Duquesnoy.   

Abstract

HLAMatchmaker is a matching algorithm that can be used to characterize antibodies specific for structurally defined epitopes. Under the auspices of the 15(th) International Histocompatibility Workshop, we are conducting a multilaboratory collaborative project to characterize these epitopes and also to determine how often they induce specific antibodies in patients with rejected kidney transplants. This report addresses the reactivity of post-allograft nephrectomy sera tested for DRB antibodies with Luminex assays using single alleles. This analysis was performed for 19 informative kidney transplant cases contributed by 13 laboratories worldwide. There were 11 cases with a single DR2 mismatch (DR15 or DR16), and nine of them (82%) showed antibodies with both DR2 and DR1. Although these antigens might share an epitope recognized by these antibodies, this interpretation is incorrect. The HLAMatchmaker analysis offers a clearly different explanation that involves antibodies induced by DR51, which commonly associates with DR2. DR51 has an epitope defined by the 96EV eplet, which is also present on DR1 but no other DR antigen. This means that the reactivity with DR51 and DR1 reflects the presence of 96EV-specific antibodies. Conversely, we analyzed eight patients sensitized by a single DR1 mismatch that has no associated DR51. All of these patients reacted also with DR51, and this could be explained only by antibodies against the shared 96EV eplet. These findings demonstrate that 96EV represents a highly immunogenic epitope that can induce cross-sensitization between antigens encoded by the different DRB loci, and also that DR51 is important in determining DRB mismatch acceptability of potential donors. This analysis has also demonstrated that antibody responses are restricted to a few epitopes on these immunizing DR antigens. For DR2 they are 142M3 (unique for DR2), 71QAA (shared with DB5*02), and 96QV (shared with DR10). DR51 mismatches appear to have three immunogenic eplets: 96EV (shared with DR1), 108T3 (unique for DR51), and 40HFD (shared with DR9). Immunogenic eplets on DR1 are 12LKF2 (unique for DR1), 14FEH (shared with DR9 and DR10), and 25HRL (shared with DR10).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275922      PMCID: PMC2725000          DOI: 10.1016/j.humimm.2009.03.005

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  23 in total

1.  HLAMatchmaker-based analysis of human monoclonal antibody reactivity demonstrates the importance of an additional contact site for specific recognition of triplet-defined epitopes.

Authors:  René J Duquesnoy; Arend Mulder; Medhat Askar; Marcelo Fernandez-Vina; Frans H J Claas
Journal:  Hum Immunol       Date:  2005-07       Impact factor: 2.850

2.  A structurally based approach to determine HLA compatibility at the humoral immune level.

Authors:  Rene J Duquesnoy
Journal:  Hum Immunol       Date:  2006-09-01       Impact factor: 2.850

3.  New HLA haplotype frequency reference standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans.

Authors:  W Klitz; M Maiers; S Spellman; L A Baxter-Lowe; B Schmeckpeper; T M Williams; M Fernandez-Viña
Journal:  Tissue Antigens       Date:  2003-10

4.  HLA-DR antibody epitopes.

Authors:  Junchao Cai; Sam Kohanof; Paul I Terasaki
Journal:  Clin Transpl       Date:  2006

5.  Predictive value of human leucocyte antigen epitope matching using HLAMatchmaker for graft outcomes in a predominantly African-American renal transplant cohort.

Authors:  Abdolreza Haririan; Omar Fagoaga; Hamidreza Daneshvar; Katherina Morawski; Dale H Sillix; Jose M El-Amm; Miguel S West; James Garnick; Stephen D Migdal; Scott A Gruber; Sandra Nehlsen-Cannarella
Journal:  Clin Transplant       Date:  2006 Mar-Apr       Impact factor: 2.863

6.  Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitized patients awaiting kidney transplantation.

Authors:  Reyna S Goodman; Craig J Taylor; Cheryl M O'Rourke; Andrew Lynch; J Andrew Bradley; Tim Key
Journal:  Transplantation       Date:  2006-05-15       Impact factor: 4.939

7.  Structurally based epitope analysis of major histocompatibility complex class I-related chain A (MICA) antibody specificity patterns.

Authors:  Rene J Duquesnoy; Justin Mostecki; Jayasree Hariharan; Ivan Balazs
Journal:  Hum Immunol       Date:  2008-10-26       Impact factor: 2.850

8.  The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens.

Authors:  Marlies K A Dankers; Marian D Witvliet; Dave L Roelen; Peter de Lange; Nelleke Korfage; Guido G Persijn; René Duquesnoy; Ilias I N Doxiadis; Frans H J Claas
Journal:  Transplantation       Date:  2004-04-27       Impact factor: 4.939

9.  Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker.

Authors:  Vasilis Kosmoliaptsis; J Andrew Bradley; Linda D Sharples; Afzal Chaudhry; Timothy Key; Reyna S Goodman; Craig J Taylor
Journal:  Transplantation       Date:  2008-06-27       Impact factor: 4.939

10.  The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome.

Authors:  Frans H J Claas; Marian D Witvliet; René J Duquesnoy; Guido G Persijn; Ilias I N Doxiadis
Journal:  Transplantation       Date:  2004-07-27       Impact factor: 4.939

View more
  2 in total

Review 1.  HLA-Epitope Matching or Eplet Risk Stratification: The Devil Is in the Details.

Authors:  Anat R Tambur
Journal:  Front Immunol       Date:  2018-08-31       Impact factor: 7.561

2.  Humoral alloimmunity in transplantation: relevance of HLA epitope antigenicity and immunogenicity.

Authors:  René J Duquesnoy
Journal:  Front Immunol       Date:  2011-11-08       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.